

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yunkang Group Limited

云康集团有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2325)

POSITIVE PROFIT ALERT

This announcement is made by Yunkang Group Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) under Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Directors**”) of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary review of the draft unaudited consolidated management accounts of the Group and other information currently available to the Board, the Group expects to record a net profit in the range of RMB3.2 million to RMB9.8 million for the year ended December 31, 2025 (the “**Reporting Period**”), as compared to a net loss of approximately RMB793.2 million for the year ended December 31, 2024. The expected turnaround from a net loss to a net profit was primarily attributable to the following reasons:

1. during the Reporting Period, the Group’s short-term performance was under pressure due to various factors including centralized procurement policies, medical insurance cost control measures and intensified industry competition. In response to adjustments brought about by the market, the Group focused on improving operational quality as its core objective by optimizing its customer mix and product portfolio, deepening cooperation within medical institution alliances, and empowering customers through in-depth services, which steadily improved its operational quality. During the Reporting Period, although the Group’s overall revenue is expected to decline as compared with the same period of last year, the rate of decline has gradually narrowed. In particular, the advantages of the diagnostic testing service business model provided to medical institution alliances have become increasingly evident, thus promoting the Group’s high-quality development;
2. during the Reporting Period, the Group enhanced operational efficiency and management quality across the entire group. Through a series of lean operational measures including strengthened cost control and precise allocation of resources, both the Group’s selling expenses and administrative expenses decreased, resulting in significant improvements in cost reduction and efficiency enhancement. Meanwhile, the Group actively optimized its debt structure and improved its capital utilization efficiency, leading to a decrease in finance costs as compared with the same period last year; and

3. during the Reporting Period, the Group consistently strengthened the management of cash and trade receivables and shortened the collection cycle, achieving certain results. The Group recovered part of the trade receivables from previous years and therefore reversed certain credit impairment losses previously provided for trade receivables. Looking ahead, the Group will continue to strengthen credit control and increase its collection efforts, adopting multiple measures to facilitate the recovery of receivables.

CAUTION STATEMENT

The Board wishes to remind the Shareholders and potential investors that the above financial data is based on the draft unaudited consolidated management accounts of the Group for the year ended December 31, 2025 and the information currently available to the Board. Such information has not been audited or reviewed by the auditors and the audit committee of the Company and is subject to adjustments upon further review. Shareholders and potential investors are advised to read carefully the annual results announcement of the Company for the year ended December 31, 2025 which is expected to be published in March 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Yunkang Group Limited
Zhang Yong
Chairman

Guangzhou, the PRC
6 March 2026

As at the date of this announcement, the Board comprises Mr. Zhang Yong as chairman and executive Director; Mr. Zhang Weijie, Dr. Wang Pinghui and Dr. Wang Ruihua as non-executive Directors; and Mr. Yu Shiyong, Mr. Xie Shaohua and Dr. Dong Min as independent non-executive Directors.